A 74-year-old woman with multiple medical problems including chronic renal failure was admitted for treatment of a diabetic foot infection. On day 12 of therapy with oral ciprofloxacin and metronidazole, the patient experienced generalized myoclonus and muscle twitching. At that time it was realized that although the ciprofloxacin regimen prescribed was a usual dose for a skin and soft-tissue infection, it was excessive for her degree of renal function This was thought to be the most likely cause of the patient's neurotoxicity. Seizure activity has been reported to occur with the quinolone antibiotics and, with the increasing use of these agents, dose reductions should be kept in mind to avoid potentially serious adverse reactions.
Get full access to this article
View all access options for this article.
References
1.
BallP. Ciprofloxacin: An overview of adverse experiences. J Antimicrob Chemother1986; 18 (suppl D): 187–93.
2.
Campou-RichardsDMMonkJPPriceA, Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs1988; 35: 373–447.
3.
ArcieriGGriffithEGruenwaldtG, Ciprofloxacin: An update on clinical experience. Am J Med1987; 82 (suppl 4A): 381–6.
4.
LebelM. Ciprofloxacin: Chemistry, mechanism of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions. Pharmacotherapy1988; 8: 3–33.
5.
CockcroftDWGaultMH. Prediction of creatinine clearance from serum creatinine. Nephron1976; 16: 31–41.
6.
AchumbaJIEtteEIThomasWOAEssienEE. Chloroquine-induced acute dystonic reactions in the presence of metronidazole. Drug Intell Clin Pharm1988; 22: 308–10.
7.
FrytakSMoertelCGChildsDS. Neurologic toxicity associated with high-dose metronidazole therapy. Ann Intern Med1978; 88: 361–2.
8.
StranzMHBradleyWE. Metronidazole (Flagyl IV, Searle). Drug Intell Clin Pharm1981; 15: 838–46.
9.
Physicians' desk reference. 43rd ed.Oradell, NJ: Medical Economics, 1989: 2012–6.
10.
WijnandsWJAVreeTBVanherwaardenCLA. The influence of quinolone derivatives on theophylline clearance. Br J Clin Pharmacol1986; 22: 677–83.
11.
WijnandsWJAVreeTBBaarsAMVanherwaardenCLA. Steady-state kinetics of the quinolone derivatives ofloxacin, enoxacin, ciprofloxacin and pefloxacin during maintenance treatment with theophylline. Drugs1987; 34 (suppl 1): 159–69.
12.
MulliganMERuanePJJohnstonL, Ciprofloxacin for eradication of methicillin-resistant Staphylococcus aureus colonization. Am J Med1987; 82 (suppl 4A): 215–9.
13.
WolfsonJSHooperDC. Norfloxacin: A new targeted fluoroquinolone antimicrobial agent. Ann Intern Med1988; 108: 238–51.
14.
AnastasioGDMenscerDLittleJMJr. Norfloxacin and seizures (letter). Ann Intern Med1988; 109: 169–70.
15.
SimpsonKJBrodieMJ. Convulsions related to enoxacin (letter). Lancet1985; 2: 161.
16.
ChristWLehnertTUlbrichB. Specific toxicologic aspects of the quinolones. Rev Infect Dis1988; 10 (suppl 1): S141–6.
17.
TsujiASatoHKumeY, Inhibitory effects of quinolone antibacterial agents on gamma-aminobutyric acid binding to receptor sites in rat brain membranes. Antimicrob Agents Chemother1988; 32: 190–4.
18.
HoriSShimadaJSaitoAMiyaharaTKuriokaSMatsudaM. Inhibitory effect of quinolones on gamma-aminobutyric acid receptor binding (abstract). Program and abstracts of the 26th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1986: 438.
19.
HoriSShimadaJSaitoAMiyaharaTKuriokaSMatsudaM. A study on enhanced epileptogenicity of new quinolones in the presence of anti-inflammatory drugs (abstract). Program and abstracts of the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1987: 30.
20.
SpectorR. Evaluation of adverse effects of drugs. In: SpectorR, ed. The scientific basis of clinical pharmacology. Principles and examples. Boston: Little, Brown, 1986: 27–41.
21.
PearsonK. The pharmacist and adverse drug reaction reporting. Hosp Pharm1982; 17: 421–30.
